Johnson & Johnson Press Releases

Financial

March 22, 2017

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Innovative Medicine

March 18, 2017

New Phase 3 Study Finds XARELTO® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism

Medical technologies

March 16, 2017

Mitek Sports Medicine Introduces Comprehensive Knee Arthroscopy Platform for ACL and Meniscal Repair

New Offering Combines Performance with Reproducibility and Operating Room Efficiency

Medical technologies

March 15, 2017

DePuy Synthes Companies Announces New ATTUNE® Revision Fixed Bearing Tibial Base and Cemented Stem for Primary and Revision Surgeries

Global Health Equity

March 14, 2017

Johnson & Johnson Reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination in Phase 1 Study

Medical technologies

March 14, 2017

New Report Demonstrates The Clinical And Economic Value Of The Attune® Knee System In Today’s Value-Based Environment

Survivorship, Economic and Patient Reported Data Are Needed to Measure Outcomes and Cost Benefits

Global Health Equity

March 14, 2017

Johnson & Johnson Names Winners of First Africa Innovation Challenge

Competition Part of Company’s Eighty-Five Year Commitment to Supporting Entrepreneurs, Science Education Opportunities, and Health Systems Across the Continent

Medical technologies

March 13, 2017

Ethicon and Depuy Synthes Introduce Customized Wound Closure Kits Aiming to Improve Efficiencies and Patient Outcomes in Orthopaedic Surgery

STRATAFIX™ and DERMABOND® advanced wound closure products are available in one convenient kit through DePuy Synthes

Innovative Medicine

March 6, 2017

Late-Breaking Results from XARELTO® (rivaroxaban) EINSTEIN CHOICE and GEMINI-ACS-1 Studies Among Research Accepted for Presentation at the American College of Cardiology 66th Annual Scientific Session

Innovative Medicine

March 3, 2017

New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira® in Treatment of Moderate to Severe Plaque Psoriasis

Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA® in the Treatment of Moderate to Severe Plaque Psoriasis

Search Results

No Results

Recently Viewed

Press releases

Press Releases